This phase III randomized trial compared two post-prostatectomy salvage radiotherapy regimens. The study team randomly assigned 316 men with intermediate- to high-risk prostate cancer between 2019 and 2021 to receive either 65 Gy in 26 fractions (hypofractionated RT, HYPO) or 66 Gy in 33 fractions (conventional RT, CONV). Treatment targeted the prostate bed; elective pelvic nodal irradiation was permitted at the treating radiation oncologist's discretion. Intensity-modulated radiotherapy with daily image guidance was used in both arms. The investigators reported that 151 patients (51.2%) received androgen deprivation therapy and that 202 men (68.5%) underwent elective nodal irradiation. Endorectal balloons were used in 186 patients (63.1%). The median pre-RT prostate-specific antigen (PSA) was 0.36 ng/mL (IQR, 0.24–0.49 ng/mL).
The primary end point was biochemical progression-free survival (bPFS). After a median follow-up of 52.6 months, the 4-year bPFS rates were 80.1% in the HYPO arm and 78.1% in the CONV arm. The study team observed that the HYPO regimen did not achieve superiority for the primary end point at four years. Secondary oncologic outcomes were similar: four-year distant metastasis-free survival (DMFS) was 91.7% versus 91.0% for HYPO and CONV, respectively, and prostate cancer-specific survival (CSS) was 100% in both arms.
Care was delivered with contemporary planning and image guidance. The investigators noted that intensity-modulated RT with daily image guidance was uniformly applied. Slightly more than half the cohort received concurrent or peri-RT androgen deprivation therapy. Elective nodal irradiation was performed in roughly two-thirds of patients, but the source did not report the specific criteria used by individual investigators to select nodal irradiation. Likewise, the source did not report detailed dose-volume constraints or specific image-guidance protocols beyond daily imaging.
The trial team reported a higher cumulative incidence of grade ≥2 gastrointestinal (GI) toxicity at four years in the HYPO arm compared with the CONV arm (7.9% v 0.7%). Most of these events occurred among patients who did not have an endorectal balloon. The authors noted that all reported GI toxicities had resolved by the last follow-up. The report did not present granular breakdowns of individual GI event types by grade and timing, nor did it give dose-volume histogram comparisons that might explain the toxicity spread.
Patient-reported quality-of-life outcomes were reported as comparable between the two arms. The source did not provide itemized domain scores in the abstract; therefore, specific patient-reported domain-level differences cannot be stated beyond the overall comparability reported by the investigators.
At the four-year landmark, oncologic control was similar whether patients received the shorter, higher-dose-per-fraction HYPO schedule or the longer CONV schedule. The trial team observed virtually identical DMFS and CSS. Those findings indicate that, within the parameters of this study, shortening treatment to 26 fractions did not worsen measured oncologic outcomes over the follow-up interval reported. The source did not provide subgroup analyses results (for example, by baseline PSA, ADT use, or nodal irradiation) in the abstract, so treatment effect heterogeneity cannot be assessed from the provided text.
Hypofractionated salvage radiotherapy, delivered as 65 Gy in 26 fractions with image guidance and intensity-modulated techniques, was feasible across participating centers. Investigators reported a higher incidence of grade ≥2 GI toxicity with HYPO, concentrated among patients without an endorectal balloon. Clinicians will need to weigh the modestly higher GI toxicity signal against the potential operational benefits of a shorter treatment course. The source did not report differences in urinary toxicity rates in the abstract, and detailed toxicity timelines and management strategies were not supplied there.
The authors concluded that hypofractionated salvage RT was not superior for bPFS at four years but may be considered an alternative given comparable oncologic outcomes and patient-reported quality-of-life. They specifically noted that additional research is needed to determine whether using an endorectal balloon reduces GI toxicity in this setting. The abstract did not provide detailed subgroup analyses, dose-volume data, or long-term toxicity beyond the median 52.6-month follow-up, and those gaps limit interpretation of late effects and effect modification. Trial registration is ClinicalTrials.gov NCT03920033.